Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1279085 | 0.98 | ALOX15 (0.39) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL1812214 | 0.98 | ALOX15 (0.39) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL1837607 | 0.98 | ALOX15 (0.39) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL242120 | 0.96 | SMN1; SMN2 (0.38) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL1812212 | 0.96 | SMN1; SMN2 (0.38) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL571438 | 0.96 | SMN1; SMN2 (0.44) | ALOX15MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL1279280 | 0.94 | SMN1; SMN2 (0.42) | ALOX15MGAMGAASIMGAM2 | |
| SCHEMBL372547 | 0.91 | — | — | |
| SCHEMBL22441532 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL20447769 | 0.89 | ALOX15 (0.42) | ALOX15MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317615-A1 | PALLADIUM (II)-CATALYZED gammaC(SP3)-H ALKYNYLATION OF AMINE2 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | US | claimed |
| US-10787418-B1 | Palladium (II)-catalyzed γC(SP3)-H alkynylation of amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-29 | — | — | US | claimed |
| CN-101239974-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | claimed |
| CN-101239975-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | claimed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | claimed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | claimed |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | DOLITZKY BEN-ZION | 2006-06-15 | — | — | US | claimed |
| CN-1771246-A | Synthesis of 2-butyl-3- (2' - (1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) -1, 3-diazaspiro [4.4] non-en-4-one | TEVA PHARMA (IL) | 2006-05-10 | — | — | CN | claimed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | claimed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| CN-113233993-B | Ferulic acid amide derivative and synthetic method thereof | 贵州大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-113233993-A | Ferulic acid amide derivative and synthetic method thereof | 贵州大学 | 2021-08-10 | — | — | CN | disclosed |
| US-20200317615-A1 | PALLADIUM (II)-CATALYZED gammaC(SP3)-H ALKYNYLATION OF AMINE2 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10787418-B1 | Palladium (II)-catalyzed γC(SP3)-H alkynylation of amines | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-29 | — | — | US | disclosed |
| US-4898930-A | Peptide derivatives and processes for their preparation | SPOFA, SPOJENE PODNIKY PRO (CS) | 1990-02-06 | — | — | US | disclosed |
| EP-0249434-A2 | Peptide derivatives and processes for their preparation | Vyzkumny ustav pro farmacii a biochemii (CZ) | 1987-12-16 | — | — | EP | disclosed |
| US-4703037-A | Angiotensin-converting enzyme inhibitors | RORER PHARMACEUTICAL CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
| US-4585758-A | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORP. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0127090-A2 | Angiotensin-converting enzyme inhibitors | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | ALOX15 2259/4885MGAM 3890/4885GAA 4080/4885 |
| US-20200317615-A1 | PALLADIUM (II)-CATALYZED gammaC(SP3)-H ALKYNYLATION OF AMINE2 | POLE3, BUB3, POLR2H | ALOX15 4745/4885MGAM 3519/4885GAA 3827/4885 |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | AGTR1, TEK, AGTR2 | ALOX15 1581/4885MGAM 3566/4885GAA 4340/4885 |
| US-10787418-B1 | Palladium (II)-catalyzed γC(SP3)-H alkynylation of amines | POLE3, BUB3, POLR2H | ALOX15 4782/4885MGAM 3117/4885GAA 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.